Aspen Neuroscience Reaches Naming Milestone for Parkinson’s Cell Therapy Candidate

According to a recent LinkedIn post from Aspen Neuroscience Inc, the World Health Organization has assigned the International Nonproprietary Name Sasineprocel to the company’s investigational autologous therapy ANPD001 for Parkinson’s disease. The post also notes clearance from the American Medical Association’s United States Adopted Names Council, with publication pending.

The company’s LinkedIn post characterizes this naming decision as an important milestone that reflects ongoing clinical and regulatory progress and the path toward planned commercialization. Sasineprocel (ANPD001) is described as being evaluated in Aspen’s Phase 1/2a ASPIRO study in moderate to advanced Parkinson’s disease, while the post reiterates that the therapy remains investigational and is not approved by any regulatory authority.

For investors, the recognition of a nonproprietary name by WHO and the AMA‑USAN framework typically marks maturation of a drug candidate toward later‑stage development and eventual market entry. The post suggests Aspen is positioning Sasineprocel within the competitive Parkinson’s and regenerative medicine landscape, and continued progress in the ASPIRO trial will likely be a key driver of the company’s valuation and partnering potential.

The emphasis on personalized, autologous cell therapy underscores Aspen’s focus on a differentiated approach that targets disease modification rather than symptomatic relief. If clinical data ultimately support the therapy’s potential to slow or stop disease progression, as the post aspires, it could strengthen Aspen’s strategic standing in neurodegenerative therapeutics and attract increased attention from biotech investors and larger pharmaceutical collaborators.